-
公开(公告)号：US20170350884A1
公开(公告)日：2017-12-07
申请号：US15521133
申请日：2015-10-22
Inventor： Wan-Uk Kim , Daehee Hwang , Yune-Jung Park , Sung Yong You , Seung-Ah Yoo
IPC: G01N33/564
CPC classification number: G01N33/564 , C12Y304/16001 , G01N2333/948 , G01N2800/102 , G01N2800/108 , G01N2800/56
Abstract: The present invention relates to a biomarker for diagnosing rheumatoid arthritis, a biomarker for diagnosing osteoporosis as a complication of rheumatoid arthritis, a biomarker for predicting the severity and prognosis of rheumatoid arthritis, and a use thereof.
-
52.发明授权公开(公告)号：US09833473B2
公开(公告)日：2017-12-05
申请号：US14508842
申请日：2014-10-07
Inventor： Ki-Yuk Chang , Eun-Ho Choo , Hyo-Eun Park , Eun-Hye Park , Dae-Seog Lim , Jun-Ho Lee
IPC: A61K35/15 , C12N5/0784 , A61K35/12
CPC classification number: A61K35/15 , A61K2035/124 , C12N5/0639 , C12N2500/84 , C12N2501/052 , C12N2501/22 , C12N2501/25 , C12N2501/998
Abstract: Provided are the tolerogenic dendritic cells for treating a myocardial infarction and a method for preparing the same, and more particularly, the tolerogenic dendritic cells for treating a myocardial infarction, which can treat cardiac insufficiency that occurs by excessive remodeling of left ventricle in the heart muscle recovery process after an acute myocardial infarction, and a method for preparing the tolergenic dendritic cells. According to the present invention, the inflammatory reaction and the excessive remodeling of left ventricle in the heart muscle recovery process after a myocardial infarction can be inhibited, and thus, the incidence rate of cardiac insufficiency can be significantly reduced, thereby being effectively used for treating a myocardial infarction.
-
公开(公告)号：US09650389B2
公开(公告)日：2017-05-16
申请号：US15029075
申请日：2014-12-30
Applicant: Korea Research Institute of Chemical Technology , The Catholic University of Korea Industry-Academic Cooperation Foundation
Inventor： Heeyeong Cho , Hee-Jong Lim , Ge Hyeong Lee , Woo Kyu Park , Hyeon Young Kim , Dae Young Jeong , Wan Uk Kim , Chul Soo Cho , Su Jung Park , Eun Jin Han
IPC: C07D491/153 , A61K31/4745
CPC classification number: C07D491/153 , A61K31/4745
Abstract: The preset invention relates to a novel 8-oxoprotoberberine derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5 containing the same as an active ingredient. The novel 8-oxoproteoberberine derivative or the pharmaceutically acceptable salt thereof according to the present invention can be useful in a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5, particularly rheumatoid arthritis or inflammatory diseases, since it is ascertained that the derivative or a pharmaceutically acceptable salt thereof has remarkably increased oral absorption compared with known protoberberine due to an improvement in the properties thereof, and inhibits the activity of NFAT5 and the secretion of inflammatory cytokines and reduces the expression of NAFT5 in mice with rheumatoid arthritis by directly inhibiting the transcription of NFT5.
-
公开(公告)号：US20170114008A1
公开(公告)日：2017-04-27
申请号：US15339410
申请日：2016-10-31
Inventor： Mi-La CHO , Dong-Yun SHIN , Sung-Hwan PARK , Chul-Woo YANG , Jong-Young CHOI , Min-Jung PARK , Hye-Jin SON , Sung-Hee LEE , Seon-Yeong LEE , Eun-Kyung KIM , Jae-Kyung KIM , Seung-Hun LEE , Seong-Hyeok PARK
IPC: C07C279/18
CPC classification number: C07C279/18 , C07C279/26
Abstract: The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present invention has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory T cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response
-
55.发明申请公开(公告)号：US20160282439A1
公开(公告)日：2016-09-29
申请号：US14685787
申请日：2015-04-14
Inventor： BO YOUNG CHOE , KYU-HO SONG , DO-WAN LEE
Abstract: The present invention relates to a phantom for evaluating performance of an ultra high field Magnetic Resonance Imaging (MRI) apparatus. Specifically, the present invention relates to a multi-purpose phantom which can grasp a degree of diagnostic capability of an MRI apparatus using a comprehensive result of imaging conditions and variables and simultaneously analyze and evaluate performance of Magnetic Resonance Imaging (MRI), performance of Magnetic Resonance Spectroscopy (MRS) and metabolic components of a human body within a predetermined range of error and limit. The phantom for evaluating performance of an ultra high field Magnetic Resonance Imaging (MRI) apparatus may include: an outer container opened and closed using a stopper and formed with an insertion hole for injecting components of a liver metabolite and a lipid; an inner container for quantitatively evaluating the components of the liver metabolite and the lipid, acquiring an MRI image using a spin echo sequence, and acquiring a relaxation time through spectroscopy using a single voxel technique of the MRI apparatus; a geometric accuracy evaluation apparatus installed at an upper end portion of the outer container in a shape of three-dimensional lattice type frame; slice position evaluation apparatuses of different shapes, capable of measuring a position of a slice in a middle of the outer container; a contrast resolution evaluation apparatus configured of a plurality of holes in the middle of the outer container to perform evaluation at regular intervals; a spatial resolution evaluation apparatus installed inside the outer container, in which a plurality of hole bundles configured of space evaluation holes is formed to have a same diameter and arranged in an evaluation frame in parallel at regular intervals to have holes of different diameters in each of the hole bundles; a slice thickness evaluation apparatus installed at a height a same as that of the spatial resolution evaluation apparatus and attached to the outer container to be formed in a shape of a stair; and a brain metabolite evaluation apparatus configured of a plurality of layers at a lower portion of the outer container.
-
Patent Agency Ranking
56.发明申请COMPOSITION FOR STABILIZING EC-SOD AND METHOD OF STABILIZING EC-SOD USING THE SAME 审中-公开用于稳定EC-SOD的组合物和使用其稳定EC-SOD的方法公开(公告)号：US20160108390A1
公开(公告)日：2016-04-21
申请号：US14721759
申请日：2015-05-26
Inventor： Tae-Yoon KIM , Sunghwan Kim , Hae-Young Kim , Jung-Ho Kim , Jung-Hye Choi , Won-Kook Ham , Yoon-Jae Jeon
CPC classification number: C12N9/96 , C12N9/0089 , C12Y115/01001
Abstract: The present invention relates to a composition for stabilizing extracellular superoxide dismutase (EC-SOD) protein and a method for stabilizing EC-SOD protein using the composition. More particularly, the present invention relates to a composition for stabilizing EC-SOD protein comprising bovine serum albumin (BSA), human serum albumin (HSA), polyethylene glycol (PEG) or fetal bovine serum (FBS) as an effective ingredient; a method for stabilizing EC-SOD protein using the inventive composition; and a method for preparing a stabilized EC-SOD protein using the inventive composition.The present invention provides a composition for stabilizing EC-SOD protein and a method for stabilizing EC-SOD using the inventive composition in order to use EC-SOD protein for clinical or non-clinical purposes. Further, the present invention attributes to the obtainment of stabilized EC-SOD protein, leading to its applicability in various medicinal and cosmetic fields.
Abstract translation: 本发明涉及用于稳定细胞外超氧化物歧化酶（EC-SOD）蛋白的组合物和使用该组合物稳定EC-SOD蛋白的方法。 更具体地说，本发明涉及用于稳定包含牛血清白蛋白（BSA），人血清白蛋白（HSA），聚乙二醇（PEG）或胎牛血清（FBS））的EC-SOD蛋白的组合物作为有效成分; 使用本发明组合物稳定EC-SOD蛋白的方法; 以及使用本发明组合物制备稳定的EC-SOD蛋白的方法。 本发明提供用于稳定EC-SOD蛋白质的组合物和使用本发明组合物稳定EC-SOD的方法，以便使用EC-SOD蛋白质用于临床或非临床目的。 此外，本发明属于稳定的EC-SOD蛋白的获得，导致其在各种医药和化妆品领域的适用性。
-
57.发明申请TOLEROGENIC DENDRITIC CELLS FOR TREATING MYOCARDIAL INFARCTION AND MANUFACTURING METHOD THEREOF 审中-公开用于治疗心肌梗塞的致敏性细胞和其制造方法公开(公告)号：US20160095882A1
公开(公告)日：2016-04-07
申请号：US14508842
申请日：2014-10-07
Inventor： Ki-Yuk Chang , Eun-Ho Choo , Hyo-Eun Park , Eun-Hye Park , Dae-Seog Lim , Jun-Ho Lee
IPC: A61K35/15 , C12N5/0784
CPC classification number: A61K35/15 , A61K2035/124 , C12N5/0639 , C12N2500/84 , C12N2501/052 , C12N2501/22 , C12N2501/25 , C12N2501/998
Abstract: Provided are the tolerogenic dendritic cells for treating a myocardial infarction and a method for preparing the same, and more particularly, the tolerogenic dendritic cells for treating a myocardial infarction, which can treat cardiac insufficiency that occurs by excessive remodeling of left ventricle in the heart muscle recovery process after an acute myocardial infarction, and a method for preparing the tolergenic dendritic cells. According to the present invention, the inflammatory reaction and the excessive remodeling of left ventricle in the heart muscle recovery process after a myocardial infarction can be inhibited, and thus, the incidence rate of cardiac insufficiency can be significantly reduced, thereby being effectively used for treating a myocardial infarction.
Abstract translation: 提供用于治疗心肌梗死的耐受性树突状细胞及其制备方法，更具体地，用于治疗心肌梗塞的耐受性树突状细胞，其可以治疗心肌中左心室过度重塑发生的心脏功能不全 急性心肌梗死后的恢复过程，以及制备易感性树突状细胞的方法。 根据本发明，可以抑制心肌梗死后心肌恢复过程中的炎症反应和过度重塑左心室，从而可以显着降低心功能不全的发生率，从而有效地用于治疗 心肌梗死。
-
58.发明申请ANTIVIRAL COMPOSITIONS COMPRISING ETHANOL EXTRACT OF TETRACERA SCANDENS AND USE THEREOF 审中-公开包含紫杉醇洗脱剂的乙醇提取物的防腐组合物及其用途公开(公告)号：US20140370127A1
公开(公告)日：2014-12-18
申请号：US14467610
申请日：2014-08-25
Inventor： Ji Chang YOU
IPC: A61K36/185
CPC classification number: A61K36/185 , A61K36/00 , A61K2236/00
Abstract: A composition for preventing or treating a viral infection, which includes an ethanol extract of Tetracera scandens as an effective component, is provided. The composition exhibits low toxicity and few side effects and effectively inhibits reverse transcriptase activities to suppress synthesis of DNA, and thus can be useful in preventing or treating infections caused by various kinds of RNA viruses.
Abstract translation: 提供了一种用于预防或治疗病毒感染的组合物，其包括作为有效成分的四氯化钪的乙醇提取物。 该组合物的毒性低，副作用小，有效抑制逆转录酶活性抑制DNA的合成，因此可用于预防或治疗由各种RNA病毒引起的感染。
-
59.发明申请NOVEL PHYTOSPHINGOSINE DERIVATIVES, AND COMPOSITION COMPRISING SAME FOR PREVENTING AND TREATING INFLAMMATORY SKIN DISEASES, AUTOIMMUNE DISEASES, AND HYPERKERATOSIS DISEASES 有权新型植酸蛋白衍生物及其组合物，用于预防和治疗炎症性皮肤病，自身免疫性疾病和高血压性疾病公开(公告)号：US20140343150A1
公开(公告)日：2014-11-20
申请号：US14299746
申请日：2014-06-09
Inventor： Byung-Hak Kim , Tae-Yoon Kim
IPC: C07C235/74 , C07C231/02
CPC classification number: C07C235/74 , A61K8/68 , A61K31/197 , A61Q19/00 , C07C231/02 , C07C235/76
Abstract: A phytosphingosine derivative of chemical formula IA or IB, and a composition comprising the phytosphingosine derivative for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratotic diseases. The phytosphingosine derivatives of the present disclosure are involved with transcription factors related to inflammation, autoimmune diseases and hyperkeratotic diseases, the expression and the generation of inflammatory mediators, signal transduction mechanisms, and the expression and the activity of relevant enzymes and the like.
Abstract translation: 化学式IA或IB的植物鞘氨醇衍生物和包含用于预防和治疗炎性皮肤病，自身免疫性疾病和角化过度疾病的植物鞘氨醇衍生物的组合物。 本公开的植物鞘氨醇衍生物涉及与炎症，自身免疫疾病和角化过度疾病相关的转录因子，炎症介质的表达和产生，信号转导机制以及相关酶等的表达和活性。
-
公开(公告)号：US20250143870A1
公开(公告)日：2025-05-08
申请号：US18938040
申请日：2024-11-05
Inventor： Dong Hyun JEE
IPC: A61F2/16
Abstract: An embodiment relates to an astigmatism axis adjustable artificial lens which is adjustable so that a correction axis of the artificial lens matches an astigmatism axis when the astigmatism axis and the correction axis of the artificial lens do not match. Here, the astigmatism axis adjustable artificial lens includes a support part and an optical lens part. The support part is fixed to a lens capsule of a patient's eye. The optical lens part is coupled to the support part and has a correction axis that matches the patient's astigmatism axis. The optical lens part is rotatably coupled to the support part to be adjustable so that the correction axis matches the patient's astigmatism axis.
-
-
-
-
-
-
-
-
-
Search Results
324
records
(took 0.032 seconds)
